UBS AM
RVMD icon

UBS AM’s Revolution Medicines RVMD Stock Holding History

UBS AM’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$171M Buy
912,335
+411,740
+82% +$60.1M 0.03% 409
2026
Q1 		$48.7M Buy
500,595
+151,183
+43% +$15.3M 0.01% 632
2025
Q4 		$27.8M Buy
349,412
+8,045
+2% +$528K 0.01% 749
2025
Q3 		$15.9M Sell
341,367
-159,330
-32% -$6.24M ﹤0.01% 916
2025
Q2 		$18.4M Buy
500,697
+200,501
+67% +$7.7M ﹤0.01% 1084
2025
Q1 		$10.6M Buy
300,196
+37,345
+14% +$1.52M ﹤0.01% 1197
2024
Q4 		$11.5M Buy
262,851
+46,825
+22% +$2.36M ﹤0.01% 1186
2024
Q3 		$9.8M Sell
216,026
-25,421
-11% -$1.11M ﹤0.01% 1233
2024
Q2 		$9.37M Buy
241,447
+108,273
+81% +$4.05M ﹤0.01% 1164
2024
Q1 		$4.29M Hold
133,174
– – ﹤0.01% 1324
2023
Q4 		$3.82M Buy
133,174
+28,936
+28% +$695K ﹤0.01% 1382
2023
Q3 		$2.89M Buy
104,238
+13,913
+15% +$413K ﹤0.01% 1447
2023
Q2 		$1.96M Hold
90,325
– – ﹤0.01% 1657
2023
Q1 		$1.96M Buy
90,325
+27,424
+44% +$675K ﹤0.01% 1657
2022
Q4 		$1.5M Buy
62,901
+18,910
+43% +$402K ﹤0.01% 1664
2022
Q3 		$868K Buy
43,991
+461
+1% +$10.1K ﹤0.01% 2049
2022
Q2 		$848K Sell
43,530
-14,008
-24% -$273K ﹤0.01% 2057
2022
Q1 		$1.47M Buy
57,538
+16,724
+41% +$364K ﹤0.01% 1951
2021
Q4 		$1.03M Buy
40,814
+1,982
+5% +$55.9K ﹤0.01% 2199
2021
Q3 		$1.07M Buy
38,832
+372
+1% +$10.8K ﹤0.01% 2135
2021
Q2 		$1.22M Buy
38,460
+16,160
+72% +$564K ﹤0.01% 2106
2021
Q1 		$1.02M Sell
22,300
-2,529
-10% -$113K ﹤0.01% 2082
2020
Q4 		$983K Buy
24,829
+17,729
+250% +$701K ﹤0.01% 2005
2020
Q3 		$247K Buy
+7,100
New +$197K ﹤0.01% 2348

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

UBS AM's RVMD Position: Q2 2026 in Review

UBS AM increased its Revolution Medicines (RVMD) stake by 82% in Q2 2026, buying an estimated $60.1M and bringing the position to 912,335 shares worth $171M. The position accounts for 0.03% of the portfolio, ranked #409.

UBS AM first reported a position in RVMD in Q3 2020 and has held it in 24 quarters since. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • UBS AM held 912,335 shares of Revolution Medicines worth $171M as of Q2 2026.
  • UBS AM bought 411,740 Revolution Medicines shares in Q2 2026, an estimated $60.1M.
  • Revolution Medicines made up 0.03% of UBS AM's portfolio in Q2 2026, its #409 holding.
  • UBS AM first reported a position in Revolution Medicines in Q3 2020 and has held it in 24 quarters since.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.